Muted Praise for Obama’s Bioeconomy Plans# Biology - 生物学
g*0
1 楼
05/01/2012 Daniel B. Moskowitz
Will President Obama’s plan help save the bioscience economy? Some industry
experts aren’t so sure.
Last week, the White House released a plan to spur the bioscience economy.
The plan outlines what it calls "a comprehensive approach to harnessing
innovations in biological research" and promises specific federal action.
The actions in this “Bioeconomy Blueprint,” which was released on April 26
, include increased government purchasing of biobased products, increased
access for researchers to data from Food and Drug Administration resources,
more help for basic science education, and new prizes and rewards for high-
risk/high-reward research. In addition, the plan calls for federal agencies
to provide new incentives for "precompetitive collaborations among private
entities to benefit the bioeconomy broadly," and for reduced barriers and
improved predictability of the regulatory process.
Will President Obama’s plan help save the bioscience economy? Some industry
experts aren’t so sure. Source: University of Pittsburgh at Bradford
By and large, those involved in biotechnology gave cautious applause to the
initiative. "The blueprint should be praised for identifying the main issues
and areas of focus that the US must address if we are to move forward as a
leader in bioscience innovation," said Holli Riebel, president of the
Colorado Bioscience Association.
Paul Pescatello, president of the New England Biotechnology Association,
likes that the administration’s plans "emphasize that breakthroughs very
much save money for our economy in the long-term."
Among the many promises, one of the most important may be improved public-
private partnerships, according to Jill Euken, deputy director of the
Bioeconomy Institute at Iowa State University. "We've found these to be very
effective," she said. "Policy is going to have more to do with how this
industry develops than technology will." In addition, Euken commended the
commitment to speeding up the federal approval process, which will ensure
that research "won't languish in the labs waiting for regulators to act."
But the praise is tempered by some skepticism. Many are uncertain whether
the administration can actually accomplish the ambitious agenda set out in
the blueprint. "In the industry, we would all love more details, more meat
on the bones," said Pescatello.
"A key question is how this report will be implemented. It will take a
continued and concerted national commitment," said Bruce Stillman, president
of Cold Spring Harbor Laboratory.
Furthermore, some are disappointed at what they feel is missing in US
President Barack Obama’s blueprint. For example, Chris Rivera, president of
the Washington Biotechnology and Biomedical Association, said that the
biggest omission was immigration law reform. Under the current laws, foreign
students trained at US universities often have difficulty getting
permission to continue working in the US after they have complete their
degrees.
Other suggestions that were submitted to the White House but not included in
the final report include much more sweeping actions. For instance, the
American Society for Biochemistry and Molecular Biology suggested that the
plan include a commitment to fight obesity, and the Pharmaceutical Research
& Manufacturers of America organization called for bigger tax credits for R&
D expenditures.
Will President Obama’s plan help save the bioscience economy? Some industry
experts aren’t so sure.
Last week, the White House released a plan to spur the bioscience economy.
The plan outlines what it calls "a comprehensive approach to harnessing
innovations in biological research" and promises specific federal action.
The actions in this “Bioeconomy Blueprint,” which was released on April 26
, include increased government purchasing of biobased products, increased
access for researchers to data from Food and Drug Administration resources,
more help for basic science education, and new prizes and rewards for high-
risk/high-reward research. In addition, the plan calls for federal agencies
to provide new incentives for "precompetitive collaborations among private
entities to benefit the bioeconomy broadly," and for reduced barriers and
improved predictability of the regulatory process.
Will President Obama’s plan help save the bioscience economy? Some industry
experts aren’t so sure. Source: University of Pittsburgh at Bradford
By and large, those involved in biotechnology gave cautious applause to the
initiative. "The blueprint should be praised for identifying the main issues
and areas of focus that the US must address if we are to move forward as a
leader in bioscience innovation," said Holli Riebel, president of the
Colorado Bioscience Association.
Paul Pescatello, president of the New England Biotechnology Association,
likes that the administration’s plans "emphasize that breakthroughs very
much save money for our economy in the long-term."
Among the many promises, one of the most important may be improved public-
private partnerships, according to Jill Euken, deputy director of the
Bioeconomy Institute at Iowa State University. "We've found these to be very
effective," she said. "Policy is going to have more to do with how this
industry develops than technology will." In addition, Euken commended the
commitment to speeding up the federal approval process, which will ensure
that research "won't languish in the labs waiting for regulators to act."
But the praise is tempered by some skepticism. Many are uncertain whether
the administration can actually accomplish the ambitious agenda set out in
the blueprint. "In the industry, we would all love more details, more meat
on the bones," said Pescatello.
"A key question is how this report will be implemented. It will take a
continued and concerted national commitment," said Bruce Stillman, president
of Cold Spring Harbor Laboratory.
Furthermore, some are disappointed at what they feel is missing in US
President Barack Obama’s blueprint. For example, Chris Rivera, president of
the Washington Biotechnology and Biomedical Association, said that the
biggest omission was immigration law reform. Under the current laws, foreign
students trained at US universities often have difficulty getting
permission to continue working in the US after they have complete their
degrees.
Other suggestions that were submitted to the White House but not included in
the final report include much more sweeping actions. For instance, the
American Society for Biochemistry and Molecular Biology suggested that the
plan include a commitment to fight obesity, and the Pharmaceutical Research
& Manufacturers of America organization called for bigger tax credits for R&
D expenditures.